Drug Sales Trends for LASIX

« Back to Dashboard

Payment Methods and Pharmacy Types for LASIX (2012)

Revenues by Pharmacy Type

Pharmacy Type	Revenues
MAIL-ORDER	$3,394,853
INSIDE ANOTHER STORE	$376,996

Units Sold by Pharmacy Type

Pharmacy Type	Units
MAIL-ORDER	192,454
INSIDE ANOTHER STORE	21,003

Revenues by Payment Method

Payment Method	Revenues
MEDICAID	$686,362
MEDICARE	$623,299

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for LASIX

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
LASIX			2022
LASIX			2021
LASIX			2020
LASIX			2019
LASIX			2018
LASIX			2017
LASIX			2016

# Lasix Market Analysis and Sales Projections: Furosemide Demand, Competition, Patents, and Generic Entry

Last updated: September 4, 2026

Lasix is the legacy brand name for furosemide, a loop diuretic used primarily to treat edema associated with heart failure, liver disease, and renal disease, and hypertension. The product has no meaningful remaining originator exclusivity in the United States. Its commercial market is mature, genericized, price-sensitive, and driven by chronic cardiovascular and renal disease prevalence rather than branded innovation.

The base-case outlook for furosemide is stable to modestly declining revenue through 2029. Unit demand should remain resilient because furosemide is inexpensive, clinically familiar, and embedded in hospital and outpatient treatment protocols. Net sales will remain under pressure from generic competition, institutional purchasing, reimbursement controls, and low-cost manufacturing.

Because Lasix is an older off-patent product, Sanofi and other historical brand owners do not report a standalone, current global Lasix revenue figure. Market projections are therefore best expressed as a furosemide-market outlook and indexed scenarios rather than as a precise Lasix brand forecast.

What is Lasix and how large is its addressable market?

Lasix contains furosemide, a high-ceiling loop diuretic that inhibits sodium and chloride reabsorption in the thick ascending limb of the loop of Henle. It is available in oral tablets, oral solution, and injectable formulations. The injection is important in acute-care settings where rapid diuresis is required.

The principal demand drivers are:

• Chronic heart failure and fluid overload
• Chronic kidney disease and nephrotic syndrome
• Cirrhosis-related edema and ascites
• Hypertension, although newer antihypertensive classes are often preferred
• Hospital treatment of acute pulmonary edema
• Veterinary use, which is outside the human prescription market

The American Heart Association estimates that more than 6 million U.S. adults live with heart failure, while global cardiovascular disease affects hundreds of millions of people. Chronic kidney disease affects more than 800 million people worldwide, creating a large clinical population in which diuretic therapy may be used, although not every patient receives furosemide.[1,2]

The addressable market is therefore large in patient count but modest in revenue per patient. Furosemide is typically prescribed as a low-cost generic. Market value is concentrated in higher-volume hospital channels, injectable products, combination prescriptions, and certain international markets where generic prices are higher than in the United States.

How much are Lasix and furosemide sales worth?

No reliable public filing provides a current, standalone global Lasix brand-sales figure. The original product has been exposed to generic competition for decades, and furosemide is sold by numerous manufacturers under generic and regional brand names.

The commercial structure is:

Segment	Market condition	Revenue outlook
U.S. oral tablets	Highly genericized; multiple ANDA suppliers	Flat to declining
U.S. injection	Hospital and acute-care demand; supplier concentration can affect pricing	Stable with periodic price increases
European oral products	Generic and national reimbursement markets	Low growth
Emerging markets	Higher patient growth but lower prices and uneven access	Modest unit growth
Veterinary furosemide	Established use in dogs and horses	More resilient niche growth
Branded Lasix	Limited commercial relevance	Declining or immaterial

A reasonable base case is that global furosemide prescription units grow by approximately 1% to 3% annually through 2029, while market revenue grows between negative 2% and positive 1% annually. Volume growth from aging populations and cardiovascular disease is likely to be offset by price erosion and tender-based procurement.

Indexed furosemide market projections

The following index uses 2024 market revenue as 100. It is a scenario model for the human furosemide market, not reported Lasix sales.

Year	Downside case	Base case	Upside case
2024	100	100	100
2025	96	99	102
2026	92	98	104
2027	88	97	106
2028	84	96	108
2029	80	95	110
2024-2029 CAGR	-4.4%	-1.0%	1.9%

The downside scenario assumes intensified generic bidding, hospital formulary substitution, and continued oral price erosion. The base case assumes stable use in heart failure and kidney disease, offset by generic pricing pressure. The upside case assumes rising diagnosis and treatment of heart failure, supply disruptions affecting injectable products, and stronger demand in emerging markets.

When does Lasix lose exclusivity?

Lasix lost practical market exclusivity many years ago. Furosemide is an established small-molecule generic, and the relevant U.S. regulatory pathway is the Abbreviated New Drug Application, or ANDA.

The original product’s commercial protection is no longer a barrier to generic entry. Current competitors do not need to wait for a future basic-compound patent expiration to enter the market. Any remaining protection would relate to a particular formulation, manufacturing process, device, or later-developed use rather than to furosemide itself.

What is the Orange Book status of Lasix?

The FDA Orange Book identifies approved drug products and, where applicable, patent and regulatory exclusivity information. Lasix and furosemide products have been subject to extensive generic competition, and no current basic furosemide patent should be treated as a barrier to ordinary generic tablet or injection entry.[3]

Orange Book review should distinguish among:

1. The historical Lasix reference product.
2. Current approved ANDA products.
3. Discontinued or inactive listings.
4. Patents listed against a specific NDA product.
5. Regulatory exclusivities that have already expired.

The existence of an old NDA listing does not establish current commercial exclusivity. Product status can also differ by dosage form and marketing authorization holder.

What patents protect Lasix and furosemide products?

The core furosemide molecule is long off patent. The patent estate protecting ordinary furosemide tablets and injections is therefore weak from a market-exclusion perspective.

Potentially relevant rights can include:

• Formulation patents covering modified release or liquid dosage forms
• Manufacturing-process patents
• Stability or excipient combinations
• Container-closure and packaging claims
• Combination products
• Method-of-use patents for a defined patient group or dosing regimen

These rights generally do not prevent conventional immediate-release furosemide tablets or standard injectable products from competing. A competitor would need to assess the claims and validity of each patent rather than assume that any listed patent blocks all furosemide products.

How strong is the patent estate for Lasix?

The patent estate is weak for the established product and stronger only where a supplier has created a differentiated delivery system, formulation, or combination product.

Patent category	Relevance to conventional Lasix	Commercial strength
Basic furosemide compound	Expired	None
Immediate-release tablet	Generally off patent	Low
Standard injectable furosemide	Generally off patent	Low
Modified-release formulation	Product-specific	Moderate if clinically differentiated
Liquid formulation	Product-specific	Low to moderate
Manufacturing process	May affect a supplier’s process	Usually limited
New method of use	Narrow patient or dosing scope	Variable
Device or packaging	Product-specific	Low for broad market access

No active composition-of-matter patent should be expected to support premium pricing for conventional furosemide.

Which companies compete with Lasix?

The market is fragmented. Competition comes from generic manufacturers, hospital suppliers, regional pharmaceutical companies, and branded products in selected countries.

Potential competitors include:

• Teva Pharmaceutical Industries
• Viatris
• Hikma Pharmaceuticals
• Fresenius Kabi
• Sandoz
• Zydus Pharmaceuticals
• Cipla
• Sun Pharmaceutical Industries
• Dr. Reddy’s Laboratories
• Hikma and other injectable suppliers
• Regional manufacturers supplying government and hospital tenders

The competitive set differs by dosage form. Oral tablets are widely available, while injectable furosemide can experience tighter supply conditions because sterile manufacturing has higher regulatory and operational requirements.

Lasix also competes therapeutically with other loop diuretics, including torsemide and bumetanide. Torsemide can be selected where clinicians seek more predictable oral absorption or longer duration. Bumetanide is used when a more potent dose-to-dose diuretic effect is required. Thiazide-type diuretics and mineralocorticoid receptor antagonists compete in selected hypertension and heart-failure settings.

How does Lasix compare with torsemide and bumetanide?

Attribute	Furosemide	Torsemide	Bumetanide
Market status	Mature generic	Generic, with branded history	Generic
Main use	Edema and volume overload	Edema and heart failure	Edema and volume overload
Oral absorption	More variable	Generally more predictable	Relatively predictable
Hospital use	Very broad, including injection	Primarily oral	Oral and injectable
Cost	Usually lowest	Usually higher than furosemide	Usually higher than furosemide
Competitive risk	High substitution risk	Competes on pharmacokinetics	Niche substitution risk
Growth potential	Volume-driven	Clinical preference and guideline use	Limited, specialized

Furosemide retains a cost and familiarity advantage. Torsemide is the most credible oral competitor in heart failure, particularly where clinicians focus on absorption consistency and duration of effect. The 2023 ACC/AHA clinical guidance continues to recognize loop diuretics as important for relieving congestion in heart failure, without creating a branded exclusivity advantage for any one molecule.[4]

What regulatory status does Lasix have?

Furosemide is an FDA-approved prescription drug. FDA-approved dosage forms include tablets and injectable products marketed by multiple companies. Approval depends on the specific NDA or ANDA holder, strength, dosage form, manufacturing site, and labeling.

Key regulatory characteristics include:

• ANDA-based generic competition
• Immediate-release oral dosage forms
• Intravenous and intramuscular injectable products
• Long-standing safety and efficacy history
• No expected new-drug exclusivity for ordinary generic products
• Ongoing FDA oversight of manufacturing, sterility, labeling, and drug shortages

The injection market carries greater regulatory and operational risk than tablets. Sterile injectable manufacturers face site inspections, container-closure requirements, particulate controls, and supply-chain constraints. A quality action or manufacturing interruption can temporarily improve pricing for remaining suppliers.

Are there Paragraph IV challenges involving Lasix?

Paragraph IV litigation is primarily relevant when a generic applicant challenges a listed patent for a branded reference product. For conventional Lasix and standard furosemide products, the practical significance of new Paragraph IV challenges is limited because the molecule and ordinary dosage forms are already genericized.

Paragraph IV risk may still arise for:

• A reformulated furosemide product
• A branded liquid or modified-release product
• A combination product
• A newly approved indication
• A product with a listed formulation or method-of-use patent

For the mature Lasix market, the more important legal events are likely to involve ANDA approval, manufacturing compliance, product liability, supply contracts, or patent disputes over a specific reformulation rather than a challenge to the basic molecule.

What formulation patents could protect furosemide products?

Formulation differentiation is the principal remaining route to intellectual-property protection. Potential claims may cover:

• Extended-release tablets
• Improved dissolution or bioavailability
• Oral solutions with enhanced stability
• Pediatric formulations
• Ready-to-use injectable presentations
• Premixed infusion products
• Combination products with heart-failure medicines
• Packaging that limits light or moisture degradation

A formulation patent has commercial value only if it creates a clinically meaningful benefit and the product receives physician, payer, or hospital adoption. A narrow patent around an excipient or manufacturing parameter may not prevent substitution by a conventional generic.

What manufacturing and supply risks affect the furosemide market?

Manufacturing barriers are more relevant to injectable furosemide than to tablets. The principal risks include:

• Sterile fill-finish capacity
• Active pharmaceutical ingredient supply
• FDA warning letters or import alerts
• Concentration-specific shortages
• Hospital contracting and tender losses
• Reliance on a small number of approved facilities
• Low margins that discourage capacity expansion

Tablet production has lower technical barriers and broader supplier availability. This supports continued price competition. Injectable supply is less interchangeable in practice because hospitals may require specific concentrations, vial sizes, or ready-to-use formats.

What generic entry risks exist for Lasix?

Generic entry risk is already realized for ordinary furosemide products. A new entrant would face commercial rather than patent barriers.

The main risks are:

• Low selling prices
• High pharmacy substitution
• Formulary preference for incumbent suppliers
• Contracting pressure from group purchasing organizations
• FDA manufacturing requirements
• Limited differentiation among tablet suppliers
• Customer concentration in hospital injectable channels

A new entrant may achieve better returns in injectable products, oral solutions, veterinary formulations, or supply-constrained markets. Conventional 20 mg and 40 mg tablets are likely to remain difficult markets for premium pricing.

What revenue exposure do manufacturers have to Lasix?

For diversified pharmaceutical companies, furosemide is generally a small product within a broad generic portfolio. Revenue exposure is more material for specialized injectable manufacturers and regional suppliers with hospital contracts.

Commercial exposure can be assessed through four variables:

Variable	High-exposure profile	Low-exposure profile
Dosage form	Injectable	Commodity tablet
Customer base	Large hospital tenders	Fragmented retail
Product concentration	Few suppliers	Many suppliers
Pricing power	Shortage-driven	Reimbursement-controlled

A supplier with multiple injectable presentations may benefit from temporary shortages, but that advantage can reverse after competitors restore supply. Tablet sales are more predictable but offer limited margins.

What licensing deals and settlements affect Lasix?

There is no major current licensing transaction that controls the conventional global furosemide market. The original Lasix commercial rights have passed through historical corporate ownership, but generic furosemide is now supplied through independent manufacturing and distribution arrangements.

Settlement agreements would be relevant mainly to a later reformulation, combination product, or branded delivery system. They are not expected to determine market access for ordinary furosemide tablets or injections.

Key Takeaways

• Lasix is the historical brand for furosemide, a mature loop diuretic.
• Conventional furosemide products have no meaningful remaining composition-of-matter exclusivity.
• The U.S. market is dominated by ANDA-approved generic products.
• Current standalone Lasix brand revenue is not publicly reported in a reliable, consolidated form.
• Base-case global furosemide revenue is projected to decline about 1% annually through 2029, while units grow modestly.
• Injectable furosemide has greater supply, manufacturing, and pricing risk than oral tablets.
• Torsemide is the most important clinical competitor in chronic heart failure, but furosemide retains a cost and familiarity advantage.
• Formulation, delivery-system, and manufacturing patents may protect differentiated products, but they do not broadly block generic furosemide.
• Paragraph IV litigation is unlikely to materially change the ordinary furosemide market.
• Investment value is concentrated in supply reliability, hospital contracts, injectable capacity, and differentiated formulations rather than in the Lasix brand itself.

FAQs

Is Lasix still a branded drug?

Lasix remains a recognized brand name for furosemide, but most human prescriptions are supplied through generic furosemide products. The commercial importance of the brand is substantially lower than during its exclusivity period.

Does Medicare cover generic Lasix?

Medicare Part D plans commonly cover generic furosemide, subject to formulary placement, copay tiers, and plan requirements. Hospital-administered injectable products are generally reimbursed through institutional payment systems rather than retail pharmacy benefits.

Is furosemide more profitable in tablets or injections?

Injectable furosemide generally offers greater margin potential because sterile production is more complex and suppliers may be fewer. Tablets have broader competition and lower pricing power.

Can torsemide replace Lasix?

Torsemide can replace furosemide in selected patients, particularly when clinicians seek more predictable oral absorption or longer duration. Conversion requires clinical judgment and monitoring of renal function, electrolytes, blood pressure, and fluid status.

Will furosemide sales grow with the aging population?

Patient volume should benefit from aging and rising heart-failure and kidney-disease prevalence. Market revenue may not rise at the same rate because generic price erosion, payer controls, and hospital purchasing contracts constrain unit economics.

References

1. American Heart Association. (2024). Heart disease and stroke statistics: 2024 update. Circulation.

2. International Society of Nephrology. (2023). Global kidney health atlas. International Society of Nephrology.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov

4. Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byunn, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fedson, S. E., Fonarow, G. C., Hayek, S. S., Hernandez, A. F., Khazanie, P., Kittleson, M. M., Lee, C. S., Link, M. S., ... Yancy, C. W. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation, 145(18), e895-e1032.

5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/